COVID‐19 and myeloma clinical research – experience from the CARDAMON clinical trial
Marquita Camilleri(University College London Hospitals NHS Foundation Trust), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Elizabeth H. Phillips(University of Manchester), Lucy Pike(King's College London), James D. Cavenagh(National Health Service), Tushhar Dadaga(Cancer Research UK), Laura Clifton‐Hadley(Cancer Research UK), Sally F. Barrington(King's College London), Ceri Bygrave(Cardiff and Vale University Health Board), William Wilson(Cancer Research UK), Gavin Pang(Cancer Research UK), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Karthik Ramasamy(Oxford University Hospitals NHS Trust), Richard G. Jenner(Cancer Research UK), M.D. Chapman, Rakesh Popat(University College London Hospitals NHS Foundation Trust), Matthew Streetly(King's College - North Carolina), Jonathan Sive(University College London Hospitals NHS Foundation Trust)
Cited by 7
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
|Journal of Clinical Oncology|2014|1.6k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719